Article

The Regulation of the Pharmaceutical Industry

Adrian Towse and Patricia M. Danzon

in The Oxford Handbook of Regulation

Published in print September 2010 | ISBN: 9780199560219
Published online September 2010 | | DOI: http://dx.doi.org/10.1093/oxfordhb/9780199560219.003.0022

Series: Oxford Handbooks in Business and Management

The Regulation of the Pharmaceutical Industry

More Like This

Show all results sharing these subjects:

  • Business and Management
  • Business and Government
  • Business Strategy

GO

Show Summary Details

Preview

This article focuses on the pharmaceutical industry. The pharmaceutical industry (including biological therapies and vaccines) is heavily regulated and yet has no intrinsic natural monopoly characteristics. Indeed it is highly competitive from research through to selling. Market power is temporary and derived from public policy in the form of government-granted patents on individual products. The regulatory issues in pharmaceuticals therefore arise from a number of factors that characterise this field. This article looks at the special challenges of regulating in the face of such factors as poor observability of efficacy, high dangers of moral hazard, and the potential exclusion from desirable services of those who lack wealth. In response to the need for private sector investment in drugs and vaccines to treat Less Developed Country-only diseases, the advantages and disadvantages of ‘push’ and ‘pull’ subsidy proposals are also considered in this article.

Keywords: pharmaceutical industry; market power; public policy; government-granted patents; private sector investment

Article.  9842 words. 

Subjects: Business and Management ; Business and Government ; Business Strategy

Full text: subscription required

How to subscribe Recommend to my Librarian

Buy this work at Oxford University Press »

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.